PrimeRFP SCOUT · Federal Contract Recompete Brief

HT001425FE013Oncotype IQ genomic testing — Genomic Health, Inc

Genomic Health, Inc holds $1.1M across 14 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 2 related awards under parent HT001421A0031. The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Sep 7, 2026 PoP end — agencies typically plan 12–18 months ahead.

Defense Health Agency

Awarding office

Genomic Health, Inc

Recipient

Sep 7, 2026

PoP end

$145K

Obligated

$145K

Potential

621511

NAICS

Q301

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Genomic Health, Inc — $90

Contract facts

NONE

Contract numberHT001425FE013

Also listed asHT001421A0031-HT001425FE013

AgencyDefense Health Agency

Awarding officeDefense Health Agency

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentGenomic Health, Inc

CAGE37AM2

UEIRHN3L7SBF7J6

NAICS621511

No full NAICS 621511 intel page yet. Browse NAICS intelligence

PSCQ301

Parent IDIQ / IDVHT001421A0031

Place of performanceBETHESDA MD

Pricing typeFirm Fixed Price

Extent competedNot Competed Under SAP

PoP startSep 8, 2025

PoP end (current)Sep 7, 2026

Obligated$145K

Current value$145K

Potential value$145K

ONCOTYPE IQ GENOMIC TESTING is a federal NONE award for Defense Health Agency held by Genomic Health, Inc. Estimated value $145K ($145K obligated). Current period of performance ends Sep 7, 2026. Last award drew 1 bidder. Place of performance: BETHESDA MD.

Recompete timing

Public

● Expiring in 17 days

Current PoP ends Sep 7, 2026 (17 days remaining). Agencies typically plan 12–18 months ahead — at 0.6 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Genomic Health, Inc — $1.1M obligated across 14 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($1.1M) · all agencies

Department of Defense (DOD)$756K · 69%Department of Veterans Affairs (VA)$354K · 32%

Open full company profile →

Related awards

Same parent · incumbent

36C26223N0393

ONCOTYPE GENETIC TESTING SERVICES

$194K

Feb 23, 2028

36C26224N0385

ONCOTYPE GENETIC TESTING SERVICES

$114K

Feb 23, 2028

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract HT001425FE013?

HT001425FE013 (Oncotype IQ genomic testing) is a Defense Health Agency award with a potential value of $145K, currently held by Genomic Health, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded HT001425FE013?

Defense Health Agency awarded HT001425FE013 to Genomic Health, Inc (potential $145K).

Who is the incumbent on HT001425FE013?

Genomic Health, Inc is the incumbent with $1.1M across 14 related awards in SCOUT’s public footprint. The current period of performance ends Sep 7, 2026.

When does Genomic Health, Inc’s HT001425FE013 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 7, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 26, 2026 · refreshed monthlyLatest procurement action Sep 8, 2025